Cancer Center Amsterdam
-
Leveraging Vγ9Vδ2-T cells For Cancer Immunotherapy
King, L. A., 3 Nov 2025Research output: PhD thesis › Research HvA, graduation HvA (not in use)
-
PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironment
King, L. A., Veth, M., Roos, M., Scheffer, G. L., Popovic, M. A., de Gruijl, T. D. & van der Vliet, H. J., 29 Oct 2025, In: J. Immunother. Cancer. 13, 10, e012255.Research output: Contribution to journal › Article › Academic › peer-review
-
Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager
King, L. A., Veth, M., Iglesias-Guimarais, V., Blijdorp, I., Kloosterman, J., Vis, A. N., Roovers, R. C., Hulsik, D. L., Riedl, T., Adang, A. E. P., Parren, P. W. H. I., van Helden, P. M., de Gruijl, T. D. & van der Vliet, H. J., 20 Dec 2024, In: iScience. 27, 12, 111289.Research output: Contribution to journal › Article › Academic › peer-review
- All publications